Home › Research › Health systems and care delivery
Impact of diagnosis timing on AD cost and healthcare utilization
Wei Yao, Anya Gupta, Arjun Shrinath, Viviktha Ramesh, Jessie T. Yan, Soham Shah, Akhilesh Prasad, Elizabeth Little et al.. Alzheimer s & Dementia, 2023-12-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Early-diagnosed patients (N = 421) have a lower utilization rate of inpatient skilled nursing facility, nursing home and hospitalization than late-diagnosed patients (N = 2817) after being diagnosed with AD. We also observed average medical service cost savings in all 3 years post-index, ranging from $320 to $2556 per patient per year. Per cost allocation analysis, medical service cost savings are observed in inpatient, emergency room, inpatient SNF, urgent care, nursing home/assisted living, and observation unit. Risk adjusted cost savings with statistical significance are observed in year 3 post-index. The mean cost difference between late and early diagnoses: total cost ($15472.11), medical service ($15013.7) and medication cost ($1601.61). The study highlights opportunities for earlier diagnosis and suggests long-term healthcare savings for AD patients who have been diagnosed at MCI stage compared to patients who were directly diagnosed with AD. Further research is needed to drill down into the driver of cost savings and whether it is attributable to disease management of MCI or other complications.
What this study adds
Evidence grade: Moderate
This is a case-control study of 421 participants. This study compared patients diagnosed with Alzheimer's disease early versus late and found early-diagnosed patients had lower use of nursing homes and hospitals and some medical cost savings. It suggests earlier diagnosis may bring long-term healthcare savings, but it does not test whether earlier diagnosis changes the course of the disease, and the authors say further research is needed.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yao, W., Gupta, A., Shrinath, A., Ramesh, V., Yan, J. T., Shah, S., et al. (2023). Impact of diagnosis timing on AD cost and healthcare utilization. Alzheimer s & Dementia. https://doi.org/10.1002/alz.082773
Vancouver
Yao W, Gupta A, Shrinath A, Ramesh V, Yan JT, Shah S, et al. Impact of diagnosis timing on AD cost and healthcare utilization. Alzheimer s & Dementia. 2023. doi:10.1002/alz.082773. PMID: 39120933.
BibTeX
@article{yao2023-39120933,
author = {Yao, Wei and Gupta, Anya and Shrinath, Arjun and Ramesh, Viviktha and Yan, Jessie T. and Shah, Soham and Prasad, Akhilesh and Little, Elizabeth and others},
title = {{Impact of diagnosis timing on AD cost and healthcare utilization}},
journal = {Alzheimer s \& Dementia},
year = {2023},
doi = {10.1002/alz.082773},
pmid = {39120933},
url = {https://doi.org/10.1002/alz.082773}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Early-diagnosed patients (N = 421) have a lower utilization rate of inpatient skilled nursing facility, nursing home and hospitalization than late-diagnosed patients (N = 2817) after being diagnosed with AD.
- We also observed average medical service cost savings in all 3 years post-index, ranging from $320 to $2556 per patient per year.
- Per cost allocation analysis, medical service cost savings are observed in inpatient, emergency room, inpatient SNF, urgent care, nursing home/assisted living, and observation unit.
- Risk adjusted cost savings with statistical significance are observed in year 3 post-index.
- The mean cost difference between late and early diagnoses: total cost ($15472.11), medical service ($15013.7) and medication cost ($1601.61).
Why it matters
This study compared patients diagnosed with Alzheimer's disease early versus late and found early-diagnosed patients had lower use of nursing homes and hospitals and some medical cost savings. It suggests earlier diagnosis may bring long-term healthcare savings, but it does not test whether earlier diagnosis changes the course of the disease, and the authors say further research is needed.
Study details
- Study designcase-control study
- Participants421
- Evidence strengthModerate
How this study scored 42/100
Published in a peer-reviewed journal, and it is a case-control study. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 40 of the 96 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 421 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Roche (United States): institution h-index 221 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39120933) |
| Free to read | 2 / 2 | Free to read |
| Points | 40 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 40 of the 96 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.